At a glance
Duquesne Family Office appears in 2 funding rounds tracked by ValueAddVC since 2026. Its most recent tracked deal was Precision Neuroscience's $250M Series D round (Sep 24, 2026).
Recent changes
- Sep 24, 2026Sep 24, 2026Invested in Precision Neuroscience (Series D, $250M) GlobeNewswire
- Sep 9, 2026Sep 9, 2026Invested in Fab2 (Series A, $500M) WOWTALE
Portfolio
2 totalRecent Investment Activity
2Track record: led 0 and participated in 2 of 2 tracked venture rounds · 2 in the last 12 months
| Date | Company | Event | Role | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|---|---|
| Sep 24, 2026 | Precision Neuroscience | Series D | Participated | $250M | ~$1B | Pershing SquareLeadunverifiedAckman Oxman InstituteLeadunverifiedDuquesne Family OfficeunverifiedB CapitalARK InvestInvusMubadala CapitalMirae AssetKorea Investment PartnersHitachi VenturesJSL Health Capital | GlobeNewswire |
| Sep 9, 2026 | Fab2 | Series A | Participated | $500M | $3.7B | Fundomo ManagementLeadParadigmDuquesne Family OfficeunverifiedMaverick SiliconStepStone GroupProtagonistCorner CapitalUDC VenturesNaval Ravikant | WOWTALE |
Sector / Stage Activity
Co-Investors
12Similar Firms
overlapping sector, stage or regionValue Add Research
Latest Pulse
- Oct 8, 2026Iambic Therapeutics Sets Terms For $150M Nasdaq IPOIambic Therapeutics set terms for a $150 million Nasdaq IPO at $15-$17 a share, up sharply from the roughly $100 million it originally sought when it filed in September.→
- Sep 24, 2026Precision Neuroscience Hits $1B Valuation On $250M RaisePrecision Neuroscience closed an oversubscribed $250 million Series D co-led by Bill Ackman's Pershing Square and his new Ackman Oxman Institute, valuing the brain-computer interface company at just over $1 billion.→
- Sep 24, 2026Ackman Co-Leads Precision Neuroscience's $250M RoundPrecision Neuroscience closed an oversubscribed $250 million Series D co-led by Bill Ackman's Pershing Square, valuing the brain-computer interface company at just over $1 billion as it scales past 100 patient procedures.→
- Jun 10, 2026SonoThera Raises $125M for Ultrasound Gene TherapySonoThera closed an oversubscribed $125 million Series B led by Vida Ventures to push its ultrasound-delivered, nonviral genetic medicine platform toward its first clinical trial in Duchenne muscular dystrophy in 2027.→
Duquesne Family Office FAQ
What companies has Duquesne Family Office invested in?
Duquesne Family Office's portfolio includes Precision Neuroscience, Fab2.
Who does Duquesne Family Office co-invest with most?
In the rounds Value Add tracks, Duquesne Family Office most often invests alongside Ackman Oxman Institute (1 shared deal), ARK Invest (1 shared deal), ARK Investment Management (1 shared deal), B Capital (1 shared deal), Fundomo Management (1 shared deal).
Sources & methodologyshow
- GlobeNewswireprimary source1 fact
- WOWTALEValue Add VC data1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.